Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRICLOS is an oral solution small-molecule NDA product in pre-launch stage sponsored by Sanofi. The mechanism of action, pharmacologic class, and therapeutic indications have not been disclosed publicly. Patient population and clinical utility remain undefined at this time.
Pre-Launch
Pre-launch assets typically require full commercial build-out; expect hiring across brand, sales, and medical teams as approval approaches.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Wound Healing and Bacterial Adherence With Triclosan-Coated Sutures After Mandibular Impacted Third Molar Surgery
Started Oct 2025
Career Relevance
TRICLOS represents a greenfield opportunity for professionals seeking launch-stage exposure within a major pharmaceutical sponsor. Career impact depends entirely on approval outcome and subsequent commercial prioritization.
Brand Manager
Worked on TRICLOS at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.